MARKET

ADPT

ADPT

Adaptive Biotechnologies
NASDAQ
15.77
-0.70
-4.25%
Pre Market: 15.70 -0.07 -0.44% 08:40 02/09 EST
OPEN
17.82
PREV CLOSE
16.47
HIGH
17.98
LOW
15.07
VOLUME
66
TURNOVER
0
52 WEEK HIGH
20.76
52 WEEK LOW
6.26
MARKET CAP
2.43B
P/E (TTM)
-40.2091
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ADPT last week (0202-0206)?
Weekly Report · 11h ago
Adaptive Biotechnologies (ADPT) Q4 Loss Narrows Yet Premium Valuation Tests Bullish Narratives
Simply Wall St · 2d ago
Adaptive Biotechnologies CFO Kyle Piskel Reports Disposal of Common Shares
Reuters · 2d ago
Adaptive Biotechnologies Is Maintained at Overweight by JP Morgan
Dow Jones · 3d ago
Adaptive Biotechnologies Price Target Raised to $21.00/Share From $20.00 by JP Morgan
Dow Jones · 3d ago
JP Morgan Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $21
Benzinga · 3d ago
Adaptive Biotechnologies targets 30%+ clonoSEQ test volume growth in 2026 while expanding margins and data partnerships
Seeking Alpha · 3d ago
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Biohaven Ltd. (BHVN) and Adaptive Biotechnologies (ADPT)
TipRanks · 3d ago
More
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.

Webull offers Adaptive Biotechnologies Corp stock information, including NASDAQ: ADPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADPT stock methods without spending real money on the virtual paper trading platform.